Aspirin provocation of patients with Systemic Mastocytosis

• Conditions: Allergy; systemic mastocytosis; 10001708

• Registration Number: NL-OMON45671
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 91

Inclusion Criteria

Systemic mastocytosis, according to WHO criteria.

Exclusion Criteria

Severe of uncontrolled asthma (FEV1<70%), nasal polyps, chronic rhinosinusitis, previous anaphylaxis due to NSAID's, patients who are not able to provide follow-up information, patients who are not deemed capable of handling possible delayed anaphylaxis at home.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The frequency and severity of allergic reactions to aspirin.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- the influence of aspirin on mast cell mediators; e.g. measurement of serum<br /><br>tryptase and 11bèta-PGF2 levels and of urine leukotriene E4 and<br /><br>N-methylhistamine levels<br /><br>- daily SM-related symptoms and quality of life (questionnaires)</p><br>